1.37
+0.005(+0.36%)
Currency In USD
| Previous Close | 1.37 |
| Open | 1.38 |
| Day High | 1.38 |
| Day Low | 1.35 |
| 52-Week High | 12.45 |
| 52-Week Low | 1.26 |
| Volume | 54,933 |
| Average Volume | 2.34M |
| Market Cap | 2.05M |
| PE | 0 |
| EPS | 499.26 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 2.84 |
| Change | 0 |
If you invested $1000 in Bluejay Diagnostics, Inc. (BJDX) since IPO date, it would be worth $0.03 as of August 29, 2025 at a share price of $1.37. Whereas If you bought $1000 worth of Bluejay Diagnostics, Inc. (BJDX) shares 3 years ago, it would be worth $0.16 as of August 29, 2025 at a share price of $1.37.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bluejay Diagnostics Provides Second Quarter Business and Corporate Update
GlobeNewswire Inc.
Aug 07, 2025 10:30 PM GMT
ACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced financial results for the quar
Bluejay Diagnostics Provides Mid-Year Business and Corporate Update
GlobeNewswire Inc.
Jun 03, 2025 8:05 PM GMT
ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year b
Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting
GlobeNewswire Inc.
Apr 15, 2025 11:00 AM GMT
New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented.ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced acceptance of an abstract related to the Symphon